BeiGene | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Beigene Study ID

BGB-DXP593-102

ClinicalTrials.gov ID

NCT04551898

Study Overview

Sex: All

Age: 18 Years / 65 Years

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / 65 Years

Study Documents

Study Protocol Statistical Analysis Plan